However, colorectal patients with mutated BRAF, CIMP+ and MSI-high have a better prognosis than those with traditional adenoma-to-carcinoma tumor pathway tumors, thus indicating that even among patients with a serrated phenotype, there is a marked variability in clinical outcome, according to the MS status [138,139]. The gene discussed is BRAF; the disease is adenoma.